Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06887192 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
A Phase 2 study of Psychosis Associated With Alzheimer's Disease, sponsored by MapLight Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06887192 is a Phase 2 study of Psychosis Associated With Alzheimer's Disease that is actively recruiting participants, run by MapLight Therapeutics. The registered enrollment target is 300 participants, below the 488-participant average among 4 other Psychosis Associated With Alzheimer's Disease trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT06887192, a Phase 2 study of Psychosis Associated With Alzheimer's Disease, is actively recruiting participants, sponsored by MapLight Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ML-007C-MA
Study Locations (20)
Florida
- Clinical Site - Boca Raton
- Clinical Site - Deerfield Beach
- Clinical Site - Doral
- Clinical Site - Homestead
- Clinical Site - Miami
- Clinical Site - Miami
- Clinical Site - Miami
- Clinical Site - Miami
- Clinical Site - Miami Gardens
- Clinical Site - Miami Gardens
- Clinical Site - Naples
- Clinical Site - Orlando
- Clinical Site - West Palm Beach
Arizona
- Clinical Site - Phoenix
- Clinical Site - Scottsdale
- Clinical Site - Tucson
California
- Clinical Site - Anaheim
- Clinical Site - Orange
- Clinical Site - San Diego
Nevada
- Clinical Site - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-08-15 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06887192
The ClinicalTrials.gov registry entry for NCT06887192 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 488-participant average among 4 other Psychosis Associated With Alzheimer's Disease trials with a reported enrollment target (39% lower). The listed sponsor is MapLight Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Psychosis Associated With Alzheimer's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06887192 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06887192 about?
NCT06887192 is a clinical study titled "A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis". ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primary objective is to ev...
What is the current status of trial NCT06887192?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-08-15. Estimated completion is 2027-12.
What conditions does trial NCT06887192 study?
This clinical trial studies the following conditions: Psychosis Associated With Alzheimer's Disease.
What interventions are being tested in trial NCT06887192?
The interventions under investigation include: Placebo (DRUG), ML-007C-MA (DRUG).
Who is sponsoring clinical trial NCT06887192?
This trial is sponsored by MapLight Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06887192 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psychosis Associated With Alzheimer's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
RECRUITING · Phase 2
-
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
RECRUITING · Phase 3
-
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
RECRUITING · Phase 3
-
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.